UMass Chan AffiliationsCommonwealth Medicine, Clinical Pharmacy Services
Document TypeJournal Article
Endocrine System Diseases
Health Services Administration
Health Services Research
Nutritional and Metabolic Diseases
Pharmacy and Pharmaceutical Sciences
MetadataShow full item record
AbstractNew developments that provide opportunities to enhance cost-effective diabetes care include advances in the pharmacologic treatment of diabetes, new drug delivery devices, innovations in patient management strategies, contracting strategies that incentivize effective interventions, and mobile health technologies. Payers must carefully consider the utility of these advances when making coverage decisions and designing benefits. To engage national stakeholders in a discussion about how to utilize innovations in diabetes care to optimize patient outcomes, the Academy of Managed Care Pharmacy organized the Partnership Forum on Navigating Innovations in Diabetes Care in Arlington, Virginia, on July 19-20, 2016. The forum explored current trends and advances in diabetes treatments and engaged in discussions about how organizations can leverage these emerging options to develop strategies that improve coordination of care and patient outcomes, while managing limited health resources. Additionally, stakeholders were tasked with identifying gaps in evidence that hinder decision making around novel therapies and other advances that are of direct relevance to managed care organizations.
SourceJ Manag Care Spec Pharm. 2016 Dec;22(12):1369-1375. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/27021
On July 19-20, 2016, Mark Tesell of Clinical Pharmacy Services participated in the Academy of Managed Care Pharmacy (AMCP) Partnership Forum, Navigating Innovations in Diabetes Care, in Arlington, VA. This invite-only event brought together AMCP members, industry experts, and other key healthcare stakeholders together to discuss the impact of advances in diabetes treatments related to a range of new drugs, technology solutions and care management models. Recommendations were also made to optimize care and to manage increasing cost across pharmacy and medical benefits.